Company Stemline Therapeutics, Inc.
Equities
US85858C1071
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ivan Bergstein
CEO | Chief Executive Officer | 58 | 03-08-07 |
David Gionco
DFI | Director of Finance/CFO | 63 | 14-01-15 |
Jeffrey Levitt
CMP | Compliance Officer | - | 18-02-28 |
Nassir Habboubi
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Kenneth Hoberman
COO | Chief Operating Officer | 59 | 12-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ivan Bergstein
CEO | Chief Executive Officer | 58 | 03-08-07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 52,510,785 | 52,125,679 ( 99.27 %) | 0 | 99.27 % |
Company contact information
Stemline Therapeutics, Inc.
750 Lexington Avenue 11th floor
10022, New York
+646-502-2310
http://www.stemline.comSector
1st Jan change | Capi. | |
---|---|---|
+18.77% | 125B | |
+14.05% | 108B | |
-7.16% | 23.64B | |
+3.11% | 22.39B | |
-11.21% | 17.78B | |
-41.74% | 16.43B | |
-13.47% | 16.34B | |
+2.23% | 13.56B | |
+27.13% | 11.59B |